TY - JOUR
T1 - Passive transfer of Lambert-Eaton Myasthenic Syndrome induces dihydropyridine sensitivity of I(Ca) in mouse motor nerve terminals
AU - Xu, You Fen
AU - Hewett, Sandra J.
AU - Atchison, William D.
PY - 1998/9
Y1 - 1998/9
N2 - Mice were injected for 30 days with plasma from three patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Recordings were made from the perineurial sheath of motor axon terminals of triangularis sterni muscle preparations. The objective was to characterize pharmacologically the identity of kinetically distinct, defined potential changes associated with motor nerve terminal Ca2+ currents (I(Ca)) that were affected by LEMS autoantibodies. I(Ca) elicited at 0.01 Hz were significantly reduced in amplitude by ~35% of control in LEMS-treated nerve terminals. During 10-Hz stimulation, I(Ca) amplitude was unchanged in LEMS-treated motor nerve terminals, but was depressed in control. During 20- or 100-Hz trains, facilitation of I(Ca) occurred in LEMS-treated nerve terminals whereas in control, no facilitation occurred during the trains at 20 Hz and marked depression occurred at 100 Hz. Saturation for amplitude and duration of I(Ca) in control terminals occurred at 2 and 4-6 mM extracellular Ca2+, respectively; in LEMS-treated terminals, the extracellular Ca2+ concentration had to increase by two to three times of control to cause saturation. Amplitude of the two components of I(Ca) observed when the preparation was exposed to 50 μM 3,4-diaminopyridine and 1 mM tetraethylammonium were both reduced by LEMS plasma treatment. The fast component (I(Ca,f)) was reduced by 35%, whereas the slow component (I(Ca,s)) was reduced by 37%. ω-Agatoxin IVA (ω-Aga-IVA; 0.15 μM) and ω-conotoxin- MVIIC (ω-CTx-MVIIC; 5 μM) completely blocked I(Ca) in control motor nerve terminals. The same concentrations of toxins were 20-30% less effective in blocking I(Ca) in LEMS-treated terminals. The residual I(Ca) remaining after treatment with ω-Aga-IVA or ω-CTx-MVIIC was blocked by 10 μM nifedipine and 10 μM Cd2+. Thus LEMS plasma appears to downregulate ω-Aga-IVA- sensitive (P-type) and/or ω-CTx-MVIIC-sensitive (Q-type) Ca2+ channels in murine motor nerve terminals, whereas dihydropyridine (DHP)-sensitive (L- type) Ca2+ channels are unmasked in these terminals. Acute exposure (90 min) of rat forebrain synaptosomes to LEMS immunoglobulins (Igs; 4 mg/ml) did not alter the binding of [3H]-nitrendipine or [125I]-ω-conotoxin-GVIA (- ω-CgTx GVIA) when compared with synaptosomes incubated with an equivalent concentration of control Igs. Conversely, LEMS Igs significantly decreased the B(max) for [3H]-verapamil to ~45% of control. The apparent affinity of verapamil (K(D)) for the remaining receptors was not significantly altered. Thus acute exposure of isolated central nerve terminals to LEMS Igs does not increase DHP sensitivity, whereas it reduces the number of binding sites for verapamil but not for nitrendipine or ω-CgTx-GVIA. These results suggest that chronic but not acute exposure to LEMS Igs either upregulates or unmasks DHP-sensitive Ca2+ channels in motor nerve endings.
AB - Mice were injected for 30 days with plasma from three patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Recordings were made from the perineurial sheath of motor axon terminals of triangularis sterni muscle preparations. The objective was to characterize pharmacologically the identity of kinetically distinct, defined potential changes associated with motor nerve terminal Ca2+ currents (I(Ca)) that were affected by LEMS autoantibodies. I(Ca) elicited at 0.01 Hz were significantly reduced in amplitude by ~35% of control in LEMS-treated nerve terminals. During 10-Hz stimulation, I(Ca) amplitude was unchanged in LEMS-treated motor nerve terminals, but was depressed in control. During 20- or 100-Hz trains, facilitation of I(Ca) occurred in LEMS-treated nerve terminals whereas in control, no facilitation occurred during the trains at 20 Hz and marked depression occurred at 100 Hz. Saturation for amplitude and duration of I(Ca) in control terminals occurred at 2 and 4-6 mM extracellular Ca2+, respectively; in LEMS-treated terminals, the extracellular Ca2+ concentration had to increase by two to three times of control to cause saturation. Amplitude of the two components of I(Ca) observed when the preparation was exposed to 50 μM 3,4-diaminopyridine and 1 mM tetraethylammonium were both reduced by LEMS plasma treatment. The fast component (I(Ca,f)) was reduced by 35%, whereas the slow component (I(Ca,s)) was reduced by 37%. ω-Agatoxin IVA (ω-Aga-IVA; 0.15 μM) and ω-conotoxin- MVIIC (ω-CTx-MVIIC; 5 μM) completely blocked I(Ca) in control motor nerve terminals. The same concentrations of toxins were 20-30% less effective in blocking I(Ca) in LEMS-treated terminals. The residual I(Ca) remaining after treatment with ω-Aga-IVA or ω-CTx-MVIIC was blocked by 10 μM nifedipine and 10 μM Cd2+. Thus LEMS plasma appears to downregulate ω-Aga-IVA- sensitive (P-type) and/or ω-CTx-MVIIC-sensitive (Q-type) Ca2+ channels in murine motor nerve terminals, whereas dihydropyridine (DHP)-sensitive (L- type) Ca2+ channels are unmasked in these terminals. Acute exposure (90 min) of rat forebrain synaptosomes to LEMS immunoglobulins (Igs; 4 mg/ml) did not alter the binding of [3H]-nitrendipine or [125I]-ω-conotoxin-GVIA (- ω-CgTx GVIA) when compared with synaptosomes incubated with an equivalent concentration of control Igs. Conversely, LEMS Igs significantly decreased the B(max) for [3H]-verapamil to ~45% of control. The apparent affinity of verapamil (K(D)) for the remaining receptors was not significantly altered. Thus acute exposure of isolated central nerve terminals to LEMS Igs does not increase DHP sensitivity, whereas it reduces the number of binding sites for verapamil but not for nitrendipine or ω-CgTx-GVIA. These results suggest that chronic but not acute exposure to LEMS Igs either upregulates or unmasks DHP-sensitive Ca2+ channels in motor nerve endings.
UR - http://www.scopus.com/inward/record.url?scp=0031732139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031732139&partnerID=8YFLogxK
U2 - 10.1152/jn.1998.80.3.1056
DO - 10.1152/jn.1998.80.3.1056
M3 - Article
C2 - 9744921
AN - SCOPUS:0031732139
SN - 0022-3077
VL - 80
SP - 1056
EP - 1069
JO - Journal of Neurophysiology
JF - Journal of Neurophysiology
IS - 3
ER -